BeiGene Ltd ADR BGNE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BGNE is a good fit for your portfolio.
News
-
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
-
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
-
BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment
-
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
-
BeiGene Says FDA Approves Tevimbra to Treat Some Esophageal Cancer Patients
-
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
-
Thinking about trading options or stock in NVIDIA, Tesla, Oracle, Broadcom, or Beigene?
-
BeiGene Shares Rise on First Dosing of Brukinsa
Trading Information
- Previous Close Price
- $148.56
- Day Range
- $150.73–154.47
- 52-Week Range
- $126.97–266.67
- Bid/Ask
- $140.10 / $154.00
- Market Cap
- $16.05 Bil
- Volume/Avg
- 208,460 / 224,510
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.52
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 10,000
- Website
- https://www.beigene.com
Comparables
Valuation
Metric
|
BGNE
|
09688
|
09939
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.54 | 1.93 | 0.85 |
Price/Sales | 6.52 | 5.73 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
BGNE
|
09688
|
09939
|
---|---|---|---|
Quick Ratio | 1.97 | 4.29 | 2.66 |
Current Ratio | 2.32 | 4.63 | 4.89 |
Interest Coverage | — | — | −54.22 |
Quick Ratio
BGNE
09688
09939
Profitability
Metric
|
BGNE
|
09688
|
09939
|
---|---|---|---|
Return on Assets (Normalized) | −8.47% | −22.36% | −29.60% |
Return on Equity (Normalized) | −12.68% | −26.78% | −42.85% |
Return on Invested Capital (Normalized) | −12.45% | −30.45% | −34.63% |
Return on Assets
BGNE
09688
09939
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xyvxtcprhm | Ryht | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rsjzmxyp | Vlkvfgs | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fjkprxwh | Fphnfxd | $97.8 Bil | |
MRNA
| Moderna Inc | Qzgkfwzk | Srr | $41.3 Bil | |
ARGX
| argenx SE ADR | Mmdtkpcrd | Pxl | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Wldzmbzt | Zsjv | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hsczbzgj | Plrqjs | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rfgkqkg | Trtvdb | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bfrhzlmczz | Pqmsdm | $12.5 Bil | |
INCY
| Incyte Corp | Vrptnqcz | Xqkbyq | $11.6 Bil |